$MASI (Masimo Corporation)

$MASI {{ '2015-12-17T17:51:03+0000' | timeago}} • Announcement

Developer, manufacturer and marketer of noninvasive patient monitoring products $MASI said that retired Senator Tom Harkin has been elected to the company's Board of Directors. Senator Harkin retired from the U.S. Senate in Jan. 2015 and was Chairman of the Senate HELP Committee for eight years.

$HOLX {{ '2018-01-11T21:23:15+0000' | timeago}} • Announcement

Medical technology company $HOLX has elected Namal Nawana to its board of directors, effective immediately. Nawana was formerly the CEO of Alere, Inc. Prior to that, he served Johnson & Johnson in various leadership roles, including Worldwide President of DePuy Synthes Spine.

$LGND {{ '2018-01-11T17:54:53+0000' | timeago}} • Announcement

Pharma company $LGND has signed a license agreement with Glenmark Pharmaceuticals, allowing the latter to use the OmniAb platform for discovery of antibodies. For products incorporating OmniAb antibodies, Ligand will receive annual platform access payments and royalties, while the programs will be entirely funded by Glenmark.

$LIVN {{ '2018-01-11T17:37:05+0000' | timeago}} • Announcement

$LIVN said the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study. The study is expected to enroll about 230 patients at 15 sites from the U.S. and Canada to ascertain whether valve leaflets are fully operational following surgery.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$OFIX {{ '2018-01-09T17:10:48+0000' | timeago}} • Announcement

$OFIX announced preliminary  4Q17 net sales of approx $117MM. These preliminary results represent reported sales growth of 7.7% and constant currency sales growth of 6.1% over 4Q16. As of Dec 31, 2017, cash and cash equivalents were approx $81MM compared to $40MM as of Dec 31, 2016.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$LIVN {{ '2018-01-08T14:58:25+0000' | timeago}} • Announcement

$LIVN announced Matthew J. Dodds has joined the company as SVP, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.

$HOLX {{ '2018-01-08T13:10:32+0000' | timeago}} • Announcement

Medical technology company $HOLX said it is currently looking for net revenues of about $791MM for the first quarter of 2018, higher than $775MM-$790MM the company had estimated earlier. The latest guidance represents an 8% YoY growth, reflecting the effect of divestiture of Hologic’s blood screening business and acquisition of Cynosure.

$BABY {{ '2018-01-08T12:48:13+0000' | timeago}} • Announcement

$BABY said that for FY18, the company expects revenue of $535-540MM and non-GAAP EPS of $1.60-1.65. For 1Q18, the company expects revenue of $125-127MM and non-GAAP EPS of $0.23-0.24. For 4Q17, $BABY expects to report revenue of approx. $131-132MM, while for FY17 revenue is expected to be $500.5-501.5MM.

$BABY {{ '2018-01-05T14:35:34+0000' | timeago}} • Announcement

$BABY appointed Leslie McDonnell as VP and General Manager of its Newborn Care Business Unit. McDonnell will report to CEO Jim Hawkins, and will be responsible for leading and expanding Natus' newborn care business. McDonnell is expected to join Natus on Feb. 12, 2018.

$BABY {{ '2018-01-05T14:07:05+0000' | timeago}} • Announcement

$BABY has named Leslie McDonnell as Vice President and General Manager of its Newborn Care Business Unit. Ms. McDonnell will report to Jim Hawkins, CEO. She is expected to join $BABY on February 12, 2018.

$LGND {{ '2018-01-03T14:25:12+0000' | timeago}} • Announcement

$LGND's partner HanAll Biopharma out-licensed antibody projects that were discovered by HanAll using $LGND’s OmniAb antibody discovery platform. The licensing events triggered $6MM of payments to $LGND. Including these payments, $LGND now anticipates total revenue for full year 2017 to be approx. $140MM with adjusted EPS to be $3.13-3.16.

$HOLX {{ '2018-01-03T13:10:03+0000' | timeago}} • Announcement

$HOLX said the MyoSure MANUAL device, which was designed to simplify tissue removal procedures regardless of setting, has received CE mark in Europe. The MyoSure MANUAL device joins the MyoSure suite of gynecologic surgical products that offer simple and effective solutions to resect and remove tissue.

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CNI {{ '2017-12-22T19:58:54+0000' | timeago}} • Announcement

Railroad company $CNI has decided to purchase 200 new locomotives from $GE over the next three years. Production of the locomotives will commence next year at the GE facility in Texas, and the units are expected to be delivered in 2018, 2019 and 2020. The order includes Tier-4 and Tier -3 Evolution Series locomotives.

$JNJ {{ '2017-12-21T18:10:50+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said the FDA has granted Priority Review designation for the New Drug Application (NDA) for apalutamide as treatment for non-metastatic castration-resistant prostate cancer (CRPC). This is the first agent submitted for approval to treat earlier stage castration-resistant prostate cancer at high risk for metastasis.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
RMTI (Rockwell Medical, Inc.)
Wednesday, November 8 2017 - 9:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
ELMD (Electromed, Inc.)
Wednesday, November 8 2017 - 2:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
RTIX (RTI Surgical Inc.)
Thursday, November 2 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
VAR (Varian Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
BABY (Natus Medical Inc.)
Wednesday, October 25 2017 - 3:00pm
NVS (Novartis AG)
Tuesday, October 24 2017 - 12:00pm
GE (General Electric Company)
Friday, October 20 2017 - 12:30pm

AlphaGraphics you may like